Boston Scientific Corp. (BSX) Financial Statements
Historical financial data — 42 statements covering FY2016–FY2025
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtrati...
Boston Scientific Corp.'s revenue increased 19.9% year over year, from $16.75B to $20.07B.
Net income increased 56.4% over the same period, from $1.85B to $2.90B.
Over the 9-year period from FY2016 to FY2025, revenue grew by 139% in total.
Total debt increased by 6.4% to $11.44B.
The debt-to-equity ratio stands at 0.47, indicating a moderate leverage profile.
Operating cash flow grew 32.0% to $4.53B.
Boston Scientific Corp. maintains a healthy net profit margin of 14.4%.
Recent Financial Statements
Quarterly figures are standalone quarters, de-cumulated from YTD filings (Q4 = FY − Q3 YTD when not reported).
| Period | Revenue | Net Income | Gross Profit | EBIT | Op. Cash Flow | Total Assets | Total Debt | Equity |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2024 | $4.21B+2.1% | $469.0M | $2.87B | $1.01B | $1.00B | $38.08B | $11.26B | $20.96B |
| Q4 FY2024 | $4.56B+8.4% | $565.0M | $3.12B | $393.0M | $1.46B | $39.40B | $10.75B | $21.77B |
| Q1 FY2025 | $4.66B+2.2% | $674.0M | $3.21B | $921.0M | $541.0M | $40.14B | $11.31B | $22.21B |
| Q2 FY2025 | $5.06B+8.5% | $797.0M | $3.42B | $819.0M | $1.29B | $41.56B | $11.59B | $22.42B |
| Q3 FY2025 | $5.06B+0.1% | $755.0M | $3.54B | $1.05B | $1.34B | $42.71B | $11.60B | $23.39B |
| Q4 FY2025 | $5.29B+4.4% | $672.0M | $3.68B | $825.0M | $1.36B | $43.67B | $11.44B | $24.23B |
| Q1 FY2026 | $5.20B-1.6% | $1.34B | $3.61B | $1.10B | $348.0M | $44.35B | $11.03B | $26.10B |
| Q2 FY2026 | $5.44B+4.6% | $906.0M | $3.85B | $1.18B | $1.47B | $45.22B | $12.62B | $25.17B |
Balance Sheet Summary (Q2 FY2026)
Boston Scientific Corp. (BSX) Financial Statements & Revenue History
Boston Scientific Corp. (BSX) is a US-listed stock operating in the Healthcare sector, specifically the Medical Devices industry trading at $44.20 with a market capitalization of $64. This page provides 42 historical financial statements for Boston Scientific Corp., including income statement, balance sheet, and cash flow data across multiple reporting periods. Most recently, Boston Scientific Corp. reported revenue of $20.1 billion, representing 19.9% year-over-year growth. The net profit margin of 14.4% indicates moderate profitability. The debt-to-equity ratio of 0.47 shows conservative leverage.
BSX Income Statement, Balance Sheet & Cash Flow
The financial statements table above shows Boston Scientific Corp.'s revenue, net income, gross profit, EBIT, operating cash flow, total assets, total debt, and shareholders' equity across the most recent reporting periods. Year-over-year growth rates help identify whether BSX is accelerating or decelerating in terms of top-line revenue and bottom-line profitability.
- Revenue trend: Track BSX's top-line growth across quarters and fiscal years to identify acceleration or deceleration in the business.
- Profitability: Net income and gross profit margins reveal how efficiently Boston Scientific Corp. converts revenue into earnings.
- Balance sheet health: Total assets, liabilities, debt, and equity provide a snapshot of BSX's financial position and leverage.
- Cash flow: Operating cash flow shows how much cash the business generates from its core operations, which is critical for funding dividends, buybacks, and growth.
How to Use BSX Financial Data
Investors use Boston Scientific Corp.'s financial statements to assess the company's financial health, growth trajectory, and valuation. Key metrics to focus on include:
- Revenue growth rate: Consistent double-digit revenue growth suggests a strong business; declining revenue may signal competitive pressure.
- Net profit margin: Higher margins indicate a more efficient business with pricing power. Compare BSX's margins to sector peers for context.
- Debt levels: High debt-to-equity ratios increase financial risk, especially in rising-rate environments. Low debt provides flexibility.
- Valuation multiples: See how BSX's P/E, P/S, and EV/EBITDA ratios compare to historical levels.
- Full analysis: View BSX's financial health score, earnings, and pre-market pricing.
Financial data is sourced from Boston Scientific Corp.'s SEC filings (10-K, 10-Q) via Polygon.io and Finnhub.BSX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.